Ghana approves Oxford University's malaria vaccine for children
The R21/Matrix-M malaria vaccine has scored its first regulatory clearance worldwide with an approval by FDA Ghana, Oxford University announced today. Its manufacturing partner could make 200 million doses annually.
The vaccine is approved in children 5 to 36 months old, the age group at the highest risk of death from malaria. The University of Oxford developed the vaccine with Novavax’s adjuvant technology, while the Serum Institute of India PvT (SIIPL) manufactured and scaled up the production of the jab. SIIPL is the manufacturing and commercialization license holder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.